Announcement on Conversion Result of Convertible Bonds and Share Changes
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment
Announcement on Conversion Result of Convertible Bonds and Share Changes
Filed with SSE ·
6ix hasn’t read this filing yet.
Lionco Pharmaceutical Group Co., Ltd. on 6ix
Earlier from Lionco Pharmaceutical
- Announcement on the Reply to the Inquiry Letter Regarding Matters Relating to the Earnings Forecast of Lionco Pharmaceutical Group Co., Ltd.
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- Announcement on Changing Signatory Certified Public Accountant
- Announcement on Release of Pledge of Partial Shares of Controlling Shareholders
- Announcement on Resolutions of the 6th Meeting of the 5th Board of Directors
Later from Lionco Pharmaceutical
- Announcement on Cancellation of Repurchased Shares Without Adjustment of Conversion Price for Convertible Bonds
- Announcement on Postponing Disclosure of 2025 Annual Report and Report for Q1 2026
- Announcement on the Company's and Its Wholly-owned Subsidiaries' Application for Comprehensive Credit Line from Banks in 2026 and Providing Corresponding Guarantee
- Indicative Announcement on Expected Satisfaction of Conversion Price Correction Conditions for ""Lionco Convertible Bonds"
- Announcement on Early Return of Raised Funds Temporarily Used to Supplement Current Capital
Follow Lionco Pharmaceutical into a list and get an email when it puts out news.
Follow Lionco Pharmaceutical